Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 27391387 | HLA-B*58 | metabolic syndrome | African | NA | NA | unclassified | |
| predictors of metabolic syndrome were age (per year increase odds ratio (or) = 1.12; 95% ci: 1.07 to 1.16), time postinfection (per year or = 1.47; 95% ci: 1.12 to 1.92), family history of diabetes (or = 3.13; 95% ci: 1.71 to 5.72), and the human leukocyte antigen (hla)-b*81:01 allele (or = 2.95; 95% ci: 1.21 to 7.17), whereas any hla-b*57 or b*58:01 alleles were protective (or = 0.34; 95% ci: 0.15 to 0.77). | |||||||
| 27391387 | HLA-B*81 | metabolic syndrome | African | NA | NA | unclassified | |
| predictors of metabolic syndrome were age (per year increase odds ratio (or) = 1.12; 95% ci: 1.07 to 1.16), time postinfection (per year or = 1.47; 95% ci: 1.12 to 1.92), family history of diabetes (or = 3.13; 95% ci: 1.71 to 5.72), and the human leukocyte antigen (hla)-b*81:01 allele (or = 2.95; 95% ci: 1.21 to 7.17), whereas any hla-b*57 or b*58:01 alleles were protective (or = 0.34; 95% ci: 0.15 to 0.77). | |||||||
| 30160000 | NA (NA) | metabolic syndrome | NA | insulin | NA | positive | |
| compared with patients with y-lada, patients with e-lada have better residual beta-cell function and higher level of insulin resistance (both p < .01), more metabolic syndrome characteristics, similar proportion of islet autoantibody positivity, and strikingly different hla-dq genetic background. | |||||||
| 30160000 | NA (NA) | metabolic syndrome | NA | insulin | NA | unclassified | |
| in comparison with e-t2d patients, e-lada patients tend to have similar metabolic syndrome prevalence, comparable c-peptide levels, and insulin resistance levels and share similar hla-dq genetic characteristics. | |||||||
| 30538833 | HLA-B*18 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-A*02 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-A*24 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-B*53 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-B*49 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
| 30538833 | HLA-DQA1*03 | metabolic syndrome | NA | NA | rs738409 | positive | |
| we found class i and ii hla antigens hla a24, hla b15, hla dr15, hla dr16, hla dq3 and hla dq5 more frequent in subjects with hepatic steatosis without any other risk factor and hla-a2, hla-32, hla b18, hla b49 and hla b53 in patients with obesity or metabolic syndrome. | |||||||
Copyright 2024